Tsai, MA
Fong-Ying Tsai, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20080241133 | Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 10-02-2008 |
20090068187 | Novel 14275, 54420, 8797, 27439, 68730, 69112 and 52908 molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14275, 54420, 8797, 27439, 68730, 69112 or 52908 gene has been introduced or disrupted. The invention still further provides isolated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 proteins, fusion proteins, antigenic peptides and anti-14275, 54420, 8797, 27439, 68730, 69112 or 52908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 03-12-2009 |
20090263860 | Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins, fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 10-22-2009 |
20090269350 | Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC1C, NARC 1A, NARC 25, 86604 and 32222 molecules and uses therefor - The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 10-29-2009 |
20090275050 | 14273 receptor, a novel G-protein coupled receptor - The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides. | 11-05-2009 |
20100150901 | 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 06-17-2010 |
20100291099 | NOVEL 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 AND 32222 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 11-18-2010 |
20110150860 | NOVEL 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 AND 49933 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 06-23-2011 |
20110182879 | NOVEL HUMAN TRANSFERASE FAMILY MEMBERS AND USES THEREOF - The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 46743, 27417, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 46743, 27417, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 46743, 27417, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 07-28-2011 |
Fu Sheng Tsai, Northboro, MA US
Patent application number | Description | Published |
---|---|---|
20090273312 | System and Method for Reliable Information Handling System and Battery Communication - Communication between an information handling system and battery has improved reliability by repeated communications of information from the battery using different commands from the information handling system. A battery management unit responds to a first command from an information handling system by sending information stored at a first address associated with the command and then saving the first address at second address. A power manager of the information handling system sends a second command having the second address to the battery management unit. The battery management unit responds to the second command by retrieving the first address stored at the second address, retrieving information stored at the first address and sending the information to the power manager. The power manager restricts operations of the battery, such as charges or discharges, unless the information received in response to the first and second commands matches. | 11-05-2009 |
Fu-Sheng Tsai, Northborough, MA US
Patent application number | Description | Published |
---|---|---|
20100097118 | Activating an Information Handling System Battery From a Ship Mode - In some embodiments, a method for activating an information handling system battery without using AC power is provided. One or more switches associated with a battery are maintained in a ship mode state during shipping of the information handling system such that the battery remains disconnected from particular information handling system components during shipping. In response to a user input, a power-on device generates and communicates a power-on signal to a battery management unit (BMU) of the battery. In response to receiving the power-on signal, the BMU activates the one or more switches from the ship mode state, which connects the battery to the particular information handling system components. The power-on device generates and communicates the power-on signal to the BMU, and the BMU activates the one or more switches from the ship mode state, while the information handling system is not connected to any AC power source. | 04-22-2010 |
20100277151 | Systems and methods for intelligently optimizing operating efficiency using variable gate drive voltage - Systems and methods for intelligently optimizing voltage regulation efficiency for information handling systems by varying gate drive voltage value based on measured operating efficiency and/or other voltage regulation operating parameters. Different voltage regulation operating parameters may be dynamically monitored and recorded during a power conversion process, and these operating parameters may then be used to dynamically and variably control gate drive voltage level to improve/optimize voltage regulation operating efficiency performance. | 11-04-2010 |
20110248681 | Systems and methods for configuring and charging hybrid battery systems - Systems and methods for simultaneously charging two or more cell strings of a hybrid battery system from a shared input current path to the battery system. An input common charging current may be limited to the smallest maximum allowable charging current value of multiple battery cell strings of a hybrid battery system, or may be provided as the greater of the maximum allowable charging currents of multiple battery cell strings of a hybrid battery system with current supplied to individual cell strings that require less than the maximum current being individually controlled so as not to exceed the maximum allowable current for each of the individual cell strings of the hybrid battery system. | 10-13-2011 |
20120098511 | SYSTEMS AND METHODS FOR INTELLIGENTLY OPTIMIZING OPERATING EFFICIENCY USING VARIABLE GATE DRIVE VOLTAGE - Systems and methods for intelligently optimizing voltage regulation efficiency for information handling systems by varying gate drive voltage value based on measured operating efficiency and/or other voltage regulation operating parameters. Different voltage regulation operating parameters may be dynamically monitored and recorded during a power conversion process, and these operating parameters may then be used to dynamically and variably control gate drive voltage level to improve/optimize voltage regulation operating efficiency performance. | 04-26-2012 |
Harry F. Tsai, Somerville, MA US
Patent application number | Description | Published |
---|---|---|
20120062366 | RADIO-FREQUENCY IDENTIFICATION TILES - The present disclosure is directed to methods and systems for a modular, configurable radio frequency identification (RFID) system receiving RFID communications and packaged in a casing for incorporation into a host object. The RFID system may interact with other systems based on the received RFID communications, and may include an antenna. An RFID receiver may receive RFID communications from an RFID tag via the antenna. A memory element may store a configuration for the system, which may be specific to a context of the host object and specify interactions with a second system in response to the received RFID communications. A processor may retrieve from the memory element the configuration responsive to receiving the RFID communications. A transmitter may transmit, via a second communications protocol, a request to the second system based on the interactions specified by the retrieved configuration. | 03-15-2012 |
20140299663 | SMART STORAGE SYSTEM - A system for identifying different types of products on a display hanger and determining a quantity of each of the different types of products includes a plurality of electrically conductive segments coupled to the display hanger, an electrically conductive rail coupled to the display hanger, and a sensor device electrically coupled to each of the plurality of electrically conductive segments and to the electrically conductive rail. The sensor device is configured to identify the different types of products on the display hanger and to determine the quantity of each of the different types of products based on a unique electrical signature associated with each of the different types of products. | 10-09-2014 |
20150076227 | SMART STORAGE SYSTEM - A system for identifying different types of products on a display hanger and determining a quantity of each of the different types of products includes a plurality of electrically conductive segments coupled to the display hanger, an electrically conductive rail coupled to the display hanger, and a sensor device electrically coupled to each of the plurality of electrically conductive segments and to the electrically conductive rail. The sensor device is configured to identify the different types of products on the display hanger and to determine the quantity of each of the different types of products based on a unique electrical signature associated with each of the different types of products. | 03-19-2015 |
Harry F. Tsai, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20110148591 | METHODS AND APPARATUS FOR OPERATING A RADIO DEVICE - A radio device such as a wireless tag reader communicates with multiple types of wireless identification tags in a monitored region. The radio device includes a network interface to receive messages transmitted over a network. In response to receiving a message indicating to reconfigure the radio device to support an additional wireless tag protocol, the radio is reconfigured to support communications with a corresponding new type of wireless identification tag in a monitored region. Based on this technique of reconfiguring the radio device via network messages, the radio device optionally supports additional, new or latest versions of wireless tag protocols without having to physically reprogram or replace the radio device. | 06-23-2011 |
Hsin-Yu Tsai, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20100097703 | MULTIPLE-WAVELENGTH BINARY DIFFRACTIVE LENSES - A dichromatic lens includes a plurality of zones being arranged on a lens structure, each of the zones having a specified radius and varying height. The lens structure focuses propagating light applicable to any intensity distribution for a plurality of wavelengths. | 04-22-2010 |
Larry W. Tsai, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20080261884 | Lung Volume Reduction Therapy Using Crosslinked Biopolymers - One aspect of the present invention relates to bronchoscopic lung volume reduction using solutions of biopolymers that can be polymerized in situ with a crosslinker and a polymeric additive which accelerates the cross-linking reaction. In certain embodiments, the biopolymer solutions can be in the form of a foam or gel. The biopolymer compositions disclosed herein may also be used for indications other than lung volume reduction, such as sealing fistulas or performing emergency tamponade of vessels. | 10-23-2008 |
20080281352 | Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers - One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema. | 11-13-2008 |
20100040538 | Polymer Systems for Lung Volume Reduction Therapy - One aspect of the invention relates to a hydrogel comprising a polymer comprising a plurality of pendent hydroxyl groups, a crosslinker, and a sclerosing agent. Another aspect of the invention relates to a method for reducing lung volume in a patient comprising the steps of advancing into a region of a patient's lung via said patient's trachea a multi-lumen catheter lumen through a bronchoscope; and co-administering, through the multi-lumen catheter, a first mixture comprising a first amount of a polymer containing a plurality of pendent hydroxyl groups; a second mixture comprising a second amount of a crosslinker; and a third mixture comprising a third amount of a sclerosing agent; thereby forming a hydrogel in said region. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema of the lung. | 02-18-2010 |
20120245627 | Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers - One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema. | 09-27-2012 |
20130325061 | Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers - One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema. | 12-05-2013 |
Leo Lee Tsai, Arlington, MA US
Patent application number | Description | Published |
---|---|---|
20140236120 | ADJUSTABLE STIFFNESS CATHETER - The present invention relates to a catheter that has adjustable stiffness that enables a user to select the stiffness of at least one region of the catheter during insertion and navigation through a body lumen. A preferred embodiment of the invention works in combination with a guidewire to enable placement of the catheter at a position within the vascular system, for example, to enable treatment of a variety of medical conditions. The catheter can include segments that undergo relative movement in response to actuation by the user to adjust the flexibility of the at least one region, preferably located at or near the distal end of the catheter. | 08-21-2014 |
Li-Huei Tsai, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20080300205 | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss - The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation. | 12-04-2008 |
20090111733 | PAR-4 RELATED METHODS AND COMPOSITIONS - Provided herein are methods and compositions for treating or preventing mood disorders and certain other mental disorders. Methods may comprise increasing PAR-4 levels or activity and/or the interaction between PAR-4 and the dopamine (D2) receptor | 04-30-2009 |
20100015130 | DISC-1 PATHWAY ACTIVATORS IN THE CONTROL OF NEUROGENESIS - The invention relates to methods of treating neurological disorders in a subject, by activating a DISC1 pathway. Methods of promoting neurogenesis in adult neural progenitor cells, enhancing nerve generation and treating GSK3 disorders as well as related compositions are also provided. | 01-21-2010 |
20100075926 | ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL - The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof. | 03-25-2010 |
20110009475 | METHODS FOR TREATING STRESS INDUCED EMOTIONAL DISORDERS - The invention relates to methods and products for treating emotional disorders such as stress induced emotional disorders, as well as related assays and kits. Methods include administering to a subject an effective amount of an agent for targeting the Rac1, Cdk5, p35, PAK-1 pathway to treat the emotional disorder. The agent for targeting the Rac1, Cdk5, p35, PAK-1 pathway may be, for instance a Rac-1 inhibitor, a Cdk5 inhibitor, a PAK-1 activator, or p35 mobilizing agent. | 01-13-2011 |
20110224303 | USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS - The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof. | 09-15-2011 |
20120039909 | EPIGENETIC MECHANISMS RE-ESTABLISH ACCESS TO LONG-TERM MEMORY AFTER NEURONAL LOSS - The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation. | 02-16-2012 |
20120101147 | INHIBITION OF HDAC2 TO PROMOTE MEMORY - The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished by inhibiting HDAC2 and or selectively inhibiting HDAC1/2 or HDAC1/2/3. | 04-26-2012 |
20120322879 | USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS - The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof. | 12-20-2012 |
20130004517 | DISC-1 PATHWAY ACTIVATORS IN THE CONTROL OF NEUROGENESIS - The invention relates to methods of treating neurological disorders in a subject, by activating a DISC | 01-03-2013 |
20130096129 | ACTIVATORS OF CLASS I HISTONE DEACETLYASES (HDACS) AND USES THEREOF - The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D). | 04-18-2013 |
20130197069 | METHODS FOR TREATING STRESS INDUCED EMOTIONAL DISORDERS - The invention relates to methods and products for treating emotional disorders such as stress induced emotional disorders, as well as related assays and kits. Methods include administering to a subject an effective amount of an agent for targeting the Rac1, Cdk5, p35, PAK-1 pathway to treat the emotional disorder. The agent for targeting the Rac1, Cdk5, p35, PAK-1 pathway may be, for instance, a Rac-1 inhibitor, a Cdk5 inhibitor, a PAK-1 activator, or p35 mobilizing agent. | 08-01-2013 |
20140080800 | Inhibitors of Histone Deacetylase - The present invention relates to compounds of formula (I): | 03-20-2014 |
20140080802 | Inhibitors of Histone Deacetylase - The present invention relates to compounds of formula (I): | 03-20-2014 |
Ming Tsai, Wellesley, MA US
Patent application number | Description | Published |
---|---|---|
20120128856 | MAITAKE MUSHROOM COFFEE - A method of producing a beverage including: combining roasted, ground maitake mushroom with roasted, ground coffee beans to provide a maitake-coffee mixture, and brewing the maitake-coffee mixture; and a maitake-coffee beverage produced thereby. | 05-24-2012 |
Pei-Chin Tsai, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20130224120 | MULTIMODAL DIAGNOSTIC TECHNOLOGY FOR EARLY STAGE CANCER LESIONS - Disclosed herein are compositions of a multimodal detection agent and methods of fabricating the same. The multimodal detection agent comprises a plurality of metallic nanoparticles attached to a surface of a polymeric carrier. The detection agent further comprising one or more target-specific binding agents attached to the metallic nanoparticles or the polymeric carrier. | 08-29-2013 |
Richard Tsai, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20120251586 | LIGAND-SPECIFIC INHIBITION OF ATTACHMENT OF IMMUNE CELLS TO IMPLANTABLE BIOMATERIALS - Methods for protecting biomaterials comprise attaching CD47 or Ig domain thereof to the surface of the biomaterial, thereby inhibiting or reducing immune cell attachment and/or immune cell-mediated damage to the biomaterial. Also provided are kits for practicing these methods and the protected biomaterials. | 10-04-2012 |
Richard K. Tsai, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20110105380 | Protection of Nano-Scale Particles from Immune Cell Uptake - The present invention relates to a particle. The particle has a radius of less than about 1 μm, and includes at least one peptide comprising at least a biologically active portion of CD47. The present invention also includes a method of increasing the life of a particle in vivo in a mammal, the method comprising attaching at least one peptide comprising at least a biologically active portion of CD47 to a particle and administering the particle having CD47 so attached to a mammal, wherein the administered particle has a longer half life in the mammal than an otherwise identical particle that does not have CD47 attached thereto. | 05-05-2011 |
Richard Kuo-An Tsai, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20100316570 | Protection of Virus from Immune Cell Uptake - The present invention relates to a viral particle. The viral particle has a radius of less than about 1 μm, and at least one peptide comprising at least a biologically active portion of CD47. The present invention also includes a method of increasing the life of a particle in vivo in a mammal. The method includes the steps of expressing at least one peptide comprising at least a biologically active portion of CD47 in a viral particle, and administering the viral particle having CD47 expressed to a mammal, wherein the administered viral particle has a longer half life in the mammal than an otherwise identical viral particle that does not have CD47 expressed thereon. | 12-16-2010 |
Robert Lieh-Yuan Tsai, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20100125598 | ARCHITECTURE FOR SUPPORTING SPARSE VOLUMES - An architecture, including a file-level protocol, for supporting sparse volumes on a storage system is provided. The file-level protocol provides coherency checking for use in retrieving data stored on a backing store remote from a storage system. | 05-20-2010 |
20130304844 | SYSTEM AND METHOD FOR CACHING NETWORK FILE SYSTEMS - A network caching system has a multi-protocol caching filer coupled to an origin server to provide storage virtualization of data served by the filer in response to data access requests issued by multi-protocol clients over a computer network. The multi-protocol caching filer includes a file system configured to manage a sparse volume that “virtualizes” a storage space of the data to thereby provide a cache function that enables access to data by the multi-protocol clients. To that end, the caching filer further includes a multi-protocol engine configured to translate the multi-protocol client data access requests into generic file system primitive operations executable by both the caching filer and the origin server. | 11-14-2013 |
Shengdar Tsai, Charlestown, MA US
Patent application number | Description | Published |
---|---|---|
20140295556 | Using RNA-guided FokI Nucleases (RFNs) to Increase Specificity for RNA-Guided Genome Editing - Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems. | 10-02-2014 |
Theodore Tsai, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20120093860 | INFLUENZA VACCINES WITH INCREASED AMOUNTS OF H3 ANTIGEN - An influenza vaccine includes an increased amount of H3N2 antigen relative to the normal dose. In a typical embodiment, the vaccine includes hemagglutinins from an A/H1N1 strain, an A/H3N2 strain, and a B strain, wherein (i) the weight ratio of H3N2:H1N1 hemagglutinin is greater than 1 and (ii) the weight ratio of H3N2:B hemagglutinin is greater than 1. In such a vaccine the weight ratio of H1N1:B hemagglutinin will normally be 1. For example, a vaccine may contain hemagglutinin at 15 μg for A/H1N1, 30 μg for A/H3N2 and 15 μg for B. | 04-19-2012 |
20130004942 | METHODS OF TESTING FOR INTRACELLULAR PATHOGENS - A first intracellular pathogen in a biological sample that may contain more than one intracellular pathogen is studied by a method comprising the steps of (i) contacting the sample with a population of cells in the presence of an agent inhibiting the reproduction of a second intracellular pathogen; (ii) incubating the cells under conditions that permit the reproduction of the first intracellular pathogen; and (iii) testing material arising from step (ii) for the first intracellular pathogen. | 01-03-2013 |
20140248320 | ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC PRIMING - The influenza B strain is epidemiologically relevant in the pediatric population. Immunogenic priming of children with influenza B vaccine adjuvanted with an oil-in-water emulsion primes an immune response to a booster vaccine comprising influenza B virus antigen from a different strain or lineage, irrespective of whether the booster comprises an adjuvant. | 09-04-2014 |
Theodore Tsai, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20110045022 | VACCINES INCLUDING ANTIGEN FROM FOUR STRAINS OF INFLUENZA VIRUS - Vaccines of the invention include at least four influenza virus strains. In some embodiments, the vaccines are produced in cell culture rather than in eggs. In some embodiments, the vaccines include an adjuvant. In some embodiments, the vaccines are not split or whole virion vaccines, but are live or purified glycoprotein vaccines. In some embodiments, the vaccines contain substantially the same mass of hemagglutinin (HA) for each of the influenza virus strains. In some embodiments, the four strains will include two influenza A virus strains and two influenza B virus strains (‘A-A-B-B’). In other embodiments, the four strains will include three influenza A virus strains and one influenza B virus strain (‘A-A-A-B’). | 02-24-2011 |
20140178429 | Vaccines Including Antigen From Four Strains of Influenza Virus - Vaccines of the invention include at least four influenza virus strains. In some embodiments, the vaccines are produced in cell culture rather than in eggs. In some embodiments, the vaccines include an adjuvant. In some embodiments, the vaccines are not split or whole virion vaccines, but are live or purified glycoprotein vaccines. In some embodiments, the vaccines contain substantially the same mass of hemagglutinin (HA) for each of the influenza virus strains. In some embodiments, the four strains will include two influenza A virus strains and two influenza B virus strains (‘A-A-B-B’). In other embodiments, the four strains will include three influenza A virus strains and one influenza B virus strain (‘A-A-A-B’). | 06-26-2014 |
Theodore F. Tsai, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20100010199 | MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS - Currently, the steps performed prior to release of influenza strains to vaccine manufacturers involve passaging influenza virus through eggs. The invention aims to provide procedures useful in manufacturing influenza vaccines, in which the use of eggs is reduced, and preferably is avoided altogether. For instance, rather than use chicken eggs for influenza vaccine isolation, MDCK cells (Madin Darby canine kidney cells) may be used e.g. growing in suspension, growing in a serum-free medium, growing in a protein-free medium, being non-tumorigenic, grown in the absence of an overlay medium, etc. | 01-14-2010 |
Tunglin L. Tsai, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20130088381 | SCALABLE, ANALOG MONOPULSE NETWORK - Embodiments of the concepts described herein are directed toward a common RF building block in the form of a monolithic assembly for an AESA array featuring a scalable RF design based on 2 | 04-11-2013 |